BBIO vs. ROIV

Last updated Jun 4, 2026

BBIO (BridgeBio Pharma, Inc.) and ROIV (Roivant Sciences Ltd.) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. Over the past 3 years, BBIO returned 66.21%/yr vs 44.87%/yr for ROIV. At a 0.37 correlation, their price movements are largely independent.

Performance

BBIO vs. ROIV - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in BridgeBio Pharma, Inc. (BBIO) and Roivant Sciences Ltd. (ROIV). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, BBIO achieves a -14.39% return, which is significantly lower than ROIV's 32.26% return.

BBIO

• 1D: 2.50%
• 1M: -5.09%
• YTD: -14.39%
• 6M: -11.69%
• 1Y: 74.52%
• 3Y*: 66.21%
• 5Y*: 2.47%
• 10Y*: —

ROIV

• 1D: 1.59%
• 1M: 1.20%
• YTD: 32.26%
• 6M: 38.65%
• 1Y: 155.22%
• 3Y*: 44.87%
• 5Y*: —
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

BBIO vs. ROIV - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021
BBIO BridgeBio Pharma, Inc.	-14.39%	178.75%	-32.03%	429.79%	-54.32%	-65.06%
ROIV Roivant Sciences Ltd.	32.26%	83.43%	5.34%	40.55%	-20.73%	7.81%

Correlation

The correlation between BBIO and ROIV is 0.35, which is low. Their price movements are largely independent, making them effective diversification partners.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.35
Correlation (3Y) Calculated over the trailing 3-year period	0.43
Correlation (All Time) Calculated using the full available price history since Oct 4, 2021	0.37

Fundamentals

Market Cap BBIO : $12.75B ROIV : $19.91B
EPS BBIO : -$3.76 ROIV : -$0.44
PS Ratio BBIO : 22.36 ROIV : 2.39K
Total Revenue (TTM) BBIO : $566.04M ROIV : $8.26M
Gross Profit (TTM) BBIO : $538.20M ROIV : $6.98M
EBITDA (TTM) BBIO : -$602.24M ROIV : -$316.38M

Return for Risk

BBIO vs. ROIV — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

BBIO

BBIO Risk / Return Rank: 82
BBIO Sharpe Ratio Rank: 83
BBIO Sortino Ratio Rank: 79
BBIO Omega Ratio Rank: 79
BBIO Calmar Ratio Rank: 86
BBIO Martin Ratio Rank: 86

ROIV

ROIV Risk / Return Rank: 98
ROIV Sharpe Ratio Rank: 97
ROIV Sortino Ratio Rank: 98
ROIV Omega Ratio Rank: 96
ROIV Calmar Ratio Rank: 98
ROIV Martin Ratio Rank: 98

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

BBIO vs. ROIV - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for BridgeBio Pharma, Inc. (BBIO) and Roivant Sciences Ltd. (ROIV). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	BBIO	ROIV	Difference
Sharpe ratio Return per unit of total volatility	1.61	3.79	-2.18
Sortino ratio Return per unit of downside risk	2.26	5.47	-3.21
Omega ratio Gain probability vs. loss probability	1.30	1.64	-0.33
Calmar ratio Return relative to maximum drawdown	3.70	12.17	-8.47
Martin ratio Return relative to average drawdown	9.47	39.09	-29.62
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

BBIO vs. ROIV - Sharpe Ratio Comparison

The current BBIO Sharpe Ratio is 1.61, which is lower than the ROIV Sharpe Ratio of 3.79. The chart below compares the historical Sharpe Ratios of BBIO and ROIV, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Sharpe Ratios by Period

	BBIO	ROIV	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	1.61	3.79	-2.18
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	0.03	—	—
Sharpe Ratio (All Time) Calculated using the full available price history	0.16	0.45	-0.29

Drawdowns

BBIO vs. ROIV - Drawdown Comparison

The maximum BBIO drawdown since its inception was -92.80%, which is greater than ROIV's maximum drawdown of -79.22%. Use the drawdown chart below to compare losses from any high point for BBIO and ROIV.

Drawdown Indicators

	BBIO	ROIV	Difference
Max Drawdown Largest peak-to-trough decline	-92.80%	-79.22%	-13.58%
Max Drawdown (1Y) Largest decline over 1 year	-20.25%	-12.84%	-7.41%
Max Drawdown (3Y) Largest decline over 3 years	-49.08%	-36.47%	-12.61%
Max Drawdown (5Y) Largest decline over 5 years	-91.89%	—	—
Current Drawdown Current decline from peak	-18.06%	-11.45%	-6.61%
Average Drawdown Average peak-to-trough decline	-45.85%	-27.52%	-18.33%
Ulcer Index Depth and duration of drawdowns from previous peaks	7.89%	3.99%	+3.90%

Volatility

BBIO vs. ROIV - Volatility Comparison

The current volatility for BridgeBio Pharma, Inc. (BBIO) is 11.77%, while Roivant Sciences Ltd. (ROIV) has a volatility of 16.81%. This indicates that BBIO experiences smaller price fluctuations and is considered to be less risky than ROIV based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	BBIO	ROIV	Difference
Volatility (1M) Calculated over the trailing 1-month period	11.77%	16.81%	-5.04%
Volatility (6M) Calculated over the trailing 6-month period	34.50%	34.03%	+0.47%
Volatility (1Y) Calculated over the trailing 1-year period	46.93%	41.25%	+5.68%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	86.00%	60.66%	+25.34%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	83.86%	60.66%	+23.20%

Dividends

BBIO vs. ROIV - Dividend Comparison

Neither BBIO nor ROIV has paid dividends to shareholders.

Tickers have no history of dividend payments

Financials

Frequently Asked Questions

Can I hold both BBIO and ROIV in my portfolio?

BBIO and ROIV have a correlation of 0.35, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, BBIO or ROIV?

ROIV has higher volatility (16.81%) compared to BBIO (11.77%). In terms of maximum drawdown, BBIO dropped -92.80% vs ROIV's -79.22%.

Which has better risk-adjusted returns?

ROIV currently has the higher Sharpe Ratio (3.79 vs 1.61), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.